Artificial intelligence is creating new opportunities to improve clinical development, but successful adoption requires more than choosing the latest model or launching isolated pilots. Krishna Cheriath, vice president and head of digital and AI for biopharma services at Thermo Fisher Scientific, sits down with Srivatsan Nagaraja to discuss what it takes to translate AI’s promise into measurable business and patient impact, why companies should focus on a small number of strategic imperatives, and his practical approach for prioritizing high-value use cases.

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Levine Media Group. Innehållet i podden är skapat av Levine Media Group och inte av, eller tillsammans med, Poddtoppen.